Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD of Calidi Biotherapeutics, Inc. from Q3 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Calidi Biotherapeutics, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount history and change rate from Q3 2023 to Q3 2025.
  • Calidi Biotherapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 30 Sep 2025 was $184K, a 63.1% decline year-over-year.
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

Calidi Biotherapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $184K -$314K -63.1% 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 $250K -$346K -58.1% 30 Jun 2025 10-Q 08 Aug 2025
Q1 2025 $324K -$378K -53.8% 31 Mar 2025 10-Q 14 May 2025
Q4 2024 $406K -$410K -50.2% 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 $498K -$436K -46.7% 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 $596K 30 Jun 2024 10-Q 13 Aug 2024
Q1 2024 $702K 31 Mar 2024 10-Q 14 May 2024
Q4 2023 $816K 31 Dec 2023 10-K 15 Mar 2024
Q3 2023 $934K 30 Sep 2023 10-Q 14 Nov 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.